STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE
暂无分享,去创建一个
Jenny Y Chien | S. Wrighton | J. Chien | C. Ernest | J. Gorski | S. Hall | Aroonrut Lucksiri | Steven A Wrighton | Stephen D Hall | J Christopher Gorski | Charles S Ernest | A. Lucksiri | S. Hall
[1] Malcolm Rowland,et al. Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) , 2004, AAPS PharmSci.
[2] J. Gorski,et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin , 1998, Clinical pharmacology and therapeutics.
[3] A. Rostami-Hodjegan,et al. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. , 2004, Drug discovery today. Technologies.
[4] Shiew-Mei Huang,et al. FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on Labeling , 1999, Journal of clinical pharmacology.
[5] Kiyomi Ito,et al. Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches , 2004, Pharmaceutical Research.
[6] P. Neuvonen,et al. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole , 1994 .
[7] Amin Rostami-Hodjegan,et al. The effects of dose staggering on metabolic drug-drug interactions. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[8] Walter Schmitt,et al. Physiology-based pharmacokinetic modeling: ready to be used. , 2004, Drug discovery today. Technologies.
[9] D. Warnock,et al. Pharmacokinetics of ketoconazole in normal subjects. , 1981, The Journal of antimicrobial chemotherapy.
[10] Innovation OR Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .
[11] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[12] Shiew-Mei Huang,et al. Drug‐Drug, Drug—Dietary Supplement, and Drug—Citrus Fruit and Other Food Interactions: What Have We Learned? , 2004, Journal of clinical pharmacology.
[13] S. Waldman,et al. Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity , 1999, Journal of clinical pharmacology.
[14] J B Houston,et al. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. , 2001, British journal of clinical pharmacology.
[15] A. Telenti,et al. Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity , 2004, European Journal of Clinical Pharmacology.
[16] Richard P. Lewis,et al. Pharmacokinetics of digoxin: Comparison of a two- and a three-compartment model in man , 1974, Journal of Pharmacokinetics and Biopharmaceutics.
[17] R. Austin,et al. A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.
[18] Yuichi Sugiyama,et al. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? , 2002, AAPS PharmSci.
[19] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[20] D. Shen,et al. Persistent Inhibition of CYP3A4 by Ketoconazole in Modified Caco-2 Cells , 2000, Pharmaceutical Research.
[21] S. Wrighton,et al. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. , 2002, British journal of clinical pharmacology.
[22] L. Lesko,et al. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.
[23] Amy Roe,et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[24] R. Levy,et al. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. , 2002, Journal of pharmaceutical sciences.
[25] E. Johnson,et al. Influence of food on the pharmacokinetics of ketoconazole , 1984, Antimicrobial Agents and Chemotherapy.
[26] J. Gillespie,et al. Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome , 2004, Journal of Pharmacology and Experimental Therapeutics.
[27] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[28] E. Johnson,et al. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. , 1983, The Journal of antimicrobial chemotherapy.
[29] Kiyomi Ito,et al. IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM , 2005, Drug Metabolism and Disposition.
[30] H. Kotaki,et al. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[31] Shiew-Mei Huang,et al. Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential‐toward a consensus , 2001 .
[32] Stephen D. Hall,et al. Improved prediction of drug interactions using in vivo Ki , 2004 .
[33] Malcolm Rowland,et al. Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[34] J. Heykants,et al. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers , 1986, Antimicrobial Agents and Chemotherapy.
[35] Shiew-Mei Huang,et al. Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis Issues , 1999, Journal of clinical pharmacology.
[36] Kiyomi Ito,et al. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.
[37] Malcolm Rowland,et al. Kinetics of drug-drug interactions , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[38] Y. Sugiyama,et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.
[39] Amy Roe,et al. The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective , 2003, Journal of clinical pharmacology.
[40] D. Greenblatt,et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.
[41] L. Ereshefsky,et al. Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone , 2003, Journal of clinical pharmacology.
[42] Y. Sugiyama,et al. Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. , 2003, Drug metabolism and pharmacokinetics.
[43] D. Greenblatt,et al. Kinetics and EEG Effects of Midazolam during and after 1‐Minute, 1‐Hour, and 3‐Hour Intravenous Infusions , 2004, Journal of clinical pharmacology.
[44] J. Houston,et al. Disposition of Azole Antifungal Agents. I. Nonlinearities in Ketoconazole Clearance and Binding in Rat Liver , 1993, Pharmaceutical Research.
[45] S. Wrighton,et al. Physiological approaches to the prediction of drug-drug interactions in study populations. , 2003, Current drug metabolism.
[46] W. Ambrosius,et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity , 2003, Clinical pharmacology and therapeutics.
[47] J. Gillespie,et al. Effect of Tadalafil on Cytochrome P450 3A4–mediated Clearance: Studies in Vitro and in Vivo , 2005, Clinical pharmacology and therapeutics.
[48] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.